Introduction

Cardiovascular diseases (CVDs) represent one of the leading causes of global mortality among adults and lifestyle modifications have emerged as a great opportunity to reduce their health burden [1]. Hence, changes in diet have been encouraged, as they can have a beneficial impact on the prevention, management and disease trajectory of CVDs [2]. Among currently implemented dietary interventions, increased intake of whole grains and in particular oat components, such as oat fibre and oat bioactive constituents, has been suggested to affect CVD risk markers including blood cholesterol, blood glucose and body mass index (BMI), thus reducing the risk of coronary heart disease [3,4,5,6]. There is growing evidence suggesting that oat products, when compared with similar wheat-based products or a glucose control, can have a positive effect on human glycaemic response [7]. Similar positive effects have been also reported for overall CVD risk [8], satiety [9] and increased gut microbiota diversity [10]. Currently, a considerable number of randomized controlled trials (RCTs) and reviews have documented the health benefits that oat supplementation interventions (OSIs) confer, but such efforts are limited to a basic subset of CVD risk markers [6, 11]. In addition, little attention has been given to the role of background diet and control arm in the interpretation of the relationship between OSIs and CVD markers. Differentiating such effects [12, 13] by type of dietary OSI and/or control arm (e.g., oat-free intervention, low-fat diet, wheat, rice, etc.) can aid in harnessing the potential benefits of small, but consistent dietary changes, such as supplementing one’s diet with oats. With that in mind, we aimed at examining the effect of OSIs on a more extended set of CVD risk markers, while also taking into consideration dietary backgrounds and type of control arms used in the RCTs that explored how OSIs affected CVD risk markers. Following this rationale and based on the available RCTs, three major sub-classes emerged as follows: (i) RCTs comparing an OSI vs. oat-free diet or control product without oats, (ii) intervention group combining an OSI with some type of dietary restriction (e.g., low-fat diet, hypocaloric diet, etc.) vs. the same dietary restriction alone and (iii) an OSI vs. heterogeneous control arms (e.g., rice, eggs, fibre, wheat, etc.). Based on this categorization, we assessed the association of OSIs and CVD risk markers in adults, accounting for each subclass.

Materials and methods

Search strategy and study selection

This work follows an established guide on conducting systematic reviews and meta-analyses for medical research [14], as well as PRISMA [15] guidelines for reporting. An experienced medical librarian systematically searched four electronic databases: EMBASE, MEDLINE (Ovid), Cochrane Central and Web of Science from inception until May 15, 2020 (date last searched); additionally, the first 200 results were downloaded from the Google Scholar search engine. A detailed search strategy is outlined in the supplementary material (section Search strategy). We additionally performed a hand search of the reference lists of included RCTs. Detailed inclusion and exclusion criteria can be found in the review protocol PROSPERO (ID: CRD42020189278). In brief, RCTs were included only if they (i) were conducted in humans and (ii) investigated the associations of oat, oat beta-glucan-rich extracts (OβGREs) and/or avenanthramides dietary supplementation with any of the following outcomes: serum lipid profile, glucose homeostasis parameters, inflammatory and oxidative stress markers, body morphology parameters and/or blood pressure.

Data extraction and assessment of the quality of included studies

Two reviewers, who afterwards assessed the full-texts of potentially eligible studies, independently evaluated titles and abstracts. Two reviewers also independently extracted the relevant information using a pre-defined data extraction form. Any disagreement between reviewers was settled by reaching a consensus or by consulting a third reviewer. The quality of included RCTs was assessed by two independent reviewers using the Risk of Bias Tool for Randomized Trials (Rob 2.0) [16]. Detailed information on the assessment of study quality and risk of bias is provided in Table 1.

Table 1 Study characteristics of the RCTs included in the systematic review

Statistical analysis

Treatment effects were defined as the pre-post differences in outcomes between OSIs and control arms at the end of a RCT. All outcomes were continuous, therefore, the mean differences [intervention minus control] of the treatment effects in CVD risk markers were presented as summary outcome measures. For data reported as medians, ranges or 95% confidence intervals (CI), means and standard deviations were converted as described elsewhere [17]. Random-effect models were used to obtain estimates of weighted mean differences (WMDs) and 95%CIs. For RCTs with crossover design, we used the data from the first study period only. Due to observed variations between the definition of intervention and control diet across different RCTs, we pooled the effect estimates by grouping the following type of RCTs based on background diet and control arm: (i) an OSI group compared with the same/other intervention groups, but without oats (ii) intervention group combining an OSI and some type of dietary restriction (DR) (e.g., low-fat diet, hypocaloric diet, etc.) versus the same DR without oats, and (iii) an OSI compared with other interventions (e.g. rice, eggs, fibre, wheat, etc.). Henceforth these groups will be referred to their short form as (i) OSI vs. no OSI controls, (ii) OSI + DR vs. DR alone and (iii) OSI vs. heterogeneous controls, respectively. Heterogeneity between studies was assessed using the Cochrane χ2 statistic (Pq < 0.05 was considered as significant) and the I2 statistic, and was determined as low (I2 ≤ 25%), moderate (25% < I2 < 75%), or high (I2 ≥ 75%) [18]. Study characteristics including geographic location, number of participants, duration of intervention, baseline age, health status (healthy individuals vs. those with pre-existing health conditions), and study quality were pre-specified as characteristics for assessment of heterogeneity, and were evaluated using stratified analyses and random-effects meta-regression, if eight or more studies were included in the meta-analysis [19]. We performed a leave-one-out sensitivity analysis iteratively by removing one study at a time to explore whether any single study influenced the results. Publication bias was evaluated through visual inspection of funnel plot and Egger’s test. All statistical analyses were conducted with STATA, Release 16 (Stata Corp, College Station, Texas, USA). The RCTs that could not be quantitatively pooled were qualitatively summarized.

Results

Included studies

Of 3239 unique citations yielded from the search strategy, 116 relevant full-text articles were retrieved, of which 57 RCTs met all eligibility criteria. We screened the reference lists of those 57 RCTs and identified an additional 17 studies that met all criteria. As a result, a total of 74 RCTs were included in the systematic review, comprising 4,937 individuals. Among the 74 included RCTs, only 59 could be included in the meta-analysis (Fig. 1). Twenty-nine RCTs were conducted in North America, twenty-five in Europe, thirteen in Asia–Pacific and seven in South America. The sample size ranged from 6 to 298 individuals (median 45, interquartile range (IQR): 36–60) and the duration of the interventions from 2 to 26 weeks (median 8 weeks, IQR: 4.25–12). The majority of RCTs (n = 56, 75.7%) included individuals with some form of metabolic disturbance (i.e., type 2 diabetes (T2D), metabolic syndrome, prediabetes, prehypertension, hyperlipidaemia), while only 18 RCTs were conducted in healthy individuals. The majority of the RCTs (n = 60, 81.1%) investigated oat bran, meal or porridge supplementation, 13 RCTs reported on β-glucan- containing oat products and one investigated avenanthramides (Table 1). Only 35 (47.3%) out of 74 RCTs took energy intake into account between trial arms. The majority of studies (60 out of 74, 81.1%) were evaluated as having some concerns about risk of bias, mostly due to issues linked to randomization, allocation and blinding. Ten studies (13.5%) had high risk of bias and four studies (5.4%) had low risk of bias (see Tables 1 and 2). Among the 59 RCTs included in the meta-analysis, 12 contributed to the main meta-analysis (comparing OSI vs. no OSI controls), 12 contributed to the meta-analysis comparing an OSI + DR vs. DR alone, and 35 contributed to the meta-analysis comparing an OSI vs. heterogeneous control arms.

Fig. 1
figure 1

PRISMA flowchart of selection process and included studies

Table 2 Meta-analysis of randomized clinical trials comparing oat supplementation interventions with diet or control product without oats

Meta-analysis of RCTs comparing oat supplementation interventions with the same intervention without oat product

Twelve RCTs contributed to the main meta-analysis comparing the effects of an OSI vs. no OSI controls, on CVD risk markers. In this comparison, the OSI was associated with a higher decrease in total cholesterol (TC) [WMD and (95% CI) − 0.42 mmol/L, (− 0.61; − 0.22), I2 = 96.1%, Pq < 0.001] and low-density lipoprotein cholesterol (LDL-C) [− 0.29 mmol/L, (− 0.37; − 0.20), I2 = 72.6%, Pq < 0.001] (Table 2). In addition, glucose [− 0.25 mmol/L, (− 0.36; -0.14), I2 = 47.9%, Pq = 0.15], BMI [− 0.33 kg/m2, (− 0.63; − 0.03), I2 = 55.6%, Pq = 0.09], body weight [− 0.94 kg, (− 1.84: − 0.05) I2 = 52.3%, Pq = 0.09] and waist circumference (WC) [− 1.06 cm, (− 1.85; − 0.27), I2 = 0%, Pq = 0.61] were lower in the OSI group compared to the control arm (Table 2). We found no differences in high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), or blood pressure (BP) when comparing the OSI arm to that of no OSI controls (Table 2).

Subgroup analysis, leave-one-out analysis and publication bias

Subgroup analyses, meta-regression and analysis of sources of heterogeneity were conducted only if at least 8 studies were available. We identified high heterogeneity across different studies (I2 ranged from 0 to 96.1%). Due to the limited number of studies included in our analyses, we were able to explore sources of heterogeneity only in the meta-analysis of blood lipids (subgroup analyses were not performed if less than 8 studies contributed to meta-analyses). Besides the percentage of male study participants, which was identified as potential source of heterogeneity in case of LDL-C, the heterogeneity in the other meta-analyses of blood lipids was not explained by any individual participant nor study characteristics (e.g., age, health status, number of participants, duration of intervention and location) (Supplemental Table 2). The findings were also supported by regressing continuous variables, such as age, duration of study and number of study participants—showing no evidence for linear association between those variables and WMD of TC, HDL-C, LDL-C and TGs (Supplemental Figs. 8–11). Due to the limited number of studies included, we could not stratify the meta-analyses based on intervention type (oat or OβGREs) or on intervention’s daily dose. The leave-one-out analyses did not show any study to influence the results on TC, HDL-C, LDL-C and TGs (Supplemental Tables 3–6); the leave-one-out analysis was not feasible for other outcomes due to the limited number of studies. We found no evidence for publication bias of RCTs included in meta-analysis comprising five or more estimates; funnel plots were in general symmetrical and Egger’s p values were higher than 0.05 (Supplemental Figs. 9–16).

Meta-analysis of RCTs comparing oat supplementation intervention combined with some type of dietary restriction versus the same dietary restriction alone

Data from 12 RCTs were used to compare changes in CVD risk markers between intervention groups combining an OSI with some type of DR versus DR alone. When pooling the estimates of these RCTs, we found that: (i) BMI [WMD: − 0.13 kg/m2, 95% CI (− 0.26; − 0.02), I2 = 40%, Qp = 0.13], TC [WMD: − 0.43 mmol/L, 95% CI (− 0.56; − 0.30), I2 = 91.7%, Qp < 0.001], HDL-C [WMD: − 0.05 mmol/L, 95% CI (− 0.10; − 0.006), I2 = 97.1%, Qp < 0.001], and LDL-C [WMD: − 0.26 mmol/L, 95% CI (− 0.38; − 0.14), I2 = 94.1%, Qp < 0.001] were lower in the OSI + DR group compared to DR alone arm (Table 3). No differences were seen in apolipoproteins A and B between the two groups. In addition, HbA1c and diastolic BP were lower in OSI + DR group compared to DR alone, with WMD of − 0.42 mmol/L [(− 0.48; − 0.36), I2 = 0%, Qp = 0.76] and− 1.15 mmHg [(− 2.03; − 0.28), I2 = 55.9%, Qp = 0.06], respectively (Table 3).

Table 3 Meta-analysis of randomized clinical trials comparing oat supplementation combined with some type of dietary restriction versus the same dietary restriction alone

Subgroup analysis, leave-one-out analysis and publication bias

In subgroup analyses and meta-regression, only geographic location and sex were identified as potential sources of heterogeneity for TC and LDL-C analysis, respectively, (Supplemental Table 2). The leave-one-out analyses showed that findings on TC, HDL-C, LDL-C, TGs and glucose were not driven by any single study (Supplemental Tables 7–11). Regressing continuous variables, such as age, duration of study and number of study participants, on WMD showed some evidence of linear trends between percentage of male individuals and WMD of HDL-C and LDL-C. With increasing proportions of male participants, WMD of LDL-C (p = 0.03) and TC (p = 0.51) tended to decrease, but WMD of HDL-C increased (p = 0.007), Supplemental Figs. 5–8. No evidence was found for publication bias of RCTs included in meta-analysis comprising five or more estimates (Supplemental Figs. 17–22).

Meta-analysis of RCTs comparing oat supplementation intervention versus heterogeneous control arms

A separate meta-analysis was performed including only 35 RCTs comparing CVD risk marker changes in an OSI vs. heterogeneous controls (e.g., rice, eggs, fibre, wheat, etc.). Results on blood lipid parameters remained similar to the other two meta-analyses, showing lowered TC and LDL-C in an OSI group compared to the control arms (Table 4). In addition, TGs [WMD: − 0.06 mmol/L, 95% CI (− 0.10; − 0.02)] and apolipoprotein B [WMD: − 0.03 g/L, 95% CI (− 0.05; − 0.01)] were significantly lower in the OSI arm compared to the control arm (Table 4). We found no differences for the rest of the investigated risk markers (Table 4).

Table 4 Meta-analysis of randomized clinical comparing oat supplementation intervention versus heterogeneous control arms

Qualitative data synthesis

The scarcity of studies and the diversity of control arms across trials did not permit a meta-analysis of inflammation and oxidative stress markers. A summary of these results is available in Table 1.

In one study [20], daily supplementation of the diet with oat porridge containing 3 g of beta-glucan, among hypercholesterolemic adults, for 4 weeks resulted in decreased inflammatory marker levels, including high sensitivity C–reactive protein (hsCRP), interleukin 8 (IL-8), IL-6, and tumour necrosis factor alpha (TNF-α). The OSI also increased antioxidant capacities, by increasing the oxygen radical absorbance capacity and ferric reducing ability of plasma. Consumption of rice porridge did not lead to significant changes in these measures [20]. Oat interventions differ by botanical origin, molar mass, food matrix or degree of purification, and thus may have different effects on inflammatory markers [21]. In a trial including 75 hypercholesterolemic subjects receiving either 6 g/d concentrated OβGREs or 6 g/d dextrose (control) over a 6-week period, hsCRP did not significantly change in response to OβGREs [22]. Similarly, in an RCT comparing a mixture of wheat and oats with wheat only, none of the treatments significantly affected hsCRP or IL-6 [23]. In 43 otherwise healthy men and women with increased cholesterol levels, who consumed a daily ready-meal soup low in energy and fat and high in fibre, but with OβGREs vs. the same soup without OβGREs, there were no statistically significant changes observed in hsCRP between groups [24]. A single study on the antioxidant effects of avenanthramides was found: healthy people were randomized to the OSI group with oats-derived avenanthramides capsules (containing 3.12 mg avenanthramides) or placebo (corn oil capsules) or control group (no avenanthramides) for 1 month. Reported post-treatment serum levels of superoxide dismutase and reduced glutathione were found to significantly increase by 8.4% and 17.9%, respectively (p < 0.05) [25]. While malondialdehyde level significantly decreased by 28.1%, TC, TG and LDL-C levels were lowered by 11.1%, 28.1%, and 15.1% compared to no oats and control groups, respectively.

Discussion

In this systematic review and meta-analysis, dietary OSIs were associated with some improvements in a subset of CVD risk markers independently of the dietary background or control arm (Fig. 2). In particular, OSIs showed consistent decreases for BMI, total and LDL-C levels, regardless of the background diet or comparison group. OSIs lowered levels of HbA1c, diastolic BP and HDL-C only when compared to no OSIs. Furthermore, compared to heterogeneous control arms, potential benefits of oat dietary supplementation on apolipoprotein B and TG levels were observed, in addition to improved TC and LDL-C levels. A network meta-analysis has also suggested that OSIs can help regulate TC and LDL-C, indicating that increasing oat sources of whole grain may be recommended for lipid control [26].

Fig. 2
figure 2

Graphical summary of main findings

Findings of meta-analyses have shown that intake of oat products can lower blood lipids, mainly serum LDL-C concentrations, but with a relatively modest reductions, which were variable within the range of real-world intakes. The role of oat products on lipid profile has been extensively studied in previous meta-analyses of RCTs, involving normal or mildly hypercholesterolaemic adults [6, 11, 27, 28]. Our meta-analysis included a larger number of studies, stratified the effects of an OSI by whether it was combined with another dietary restriction and demonstrated the beneficial effects of an OSI despite background diet or control arm.

Oats can exert health benefits via bioactive phytochemicals with potent antioxidant and anti-inflammatory effects, such as phytosterols, tocols, flavonoids, avenanthramides and soluble fibres such as beta-glucans [29, 30]. The cholesterol-lowering effects of soluble fibres can be partially explained by the modulating effect on absorption and re-absorption of cholesterol and bile acids due to their binding to fibre [31], or by the increased viscosity [32], which may modify the process of mixing, diffusion and/or emulsification in the gastrointestinal tract [33]. Soluble viscous fibres can influence dietary lipid metabolism in the mildly acidic medium found in the stomach [34]. Further, OβGREs have been shown to lower insulin release, which in turn can lower serum cholesterol levels [35]. Propionate produced by fermentation in the colon may inhibit cholesterol synthesis in the liver [35, 36]. This systemic interplay of oat bioactive phytochemicals and soluble fibres such as beta-glucans could have the potential to influence cardiometabolic health directly and indirectly, which warrants further investigation [4].

Apart from the lowering effect of an OSI on TC and LDL-C, a significant decrease in HDL-C was observed in the meta-analysis of RCTs comparing OSI + DR vs. DR alone. A recent RCT [37] has reported a similar HDL-C-lowering effect among patients with metabolic syndrome, in line with an RCT in 2010 [38]. This decrease in HDL-C may be linked to the background diet in the OSI group, which may have been unfavourable or influenced by confounding factors. Clinical and epidemiologic studies have established the presence of an inverse relationship between HDL-C levels and CVD risk, assuming that increased HDL-C levels are linked to protective effects on CVD [39, 40]. However, there is no sufficient evidence to show cardiovascular benefit of an OSI in patients on cholesterol-lowering therapy (e.g., statins), suggesting that HDL-C increases may not be sufficient to influence CVD risk, when LDL-C is kept in relatively low levels [41,42,43]. In addition, most research on HDL-C and Mendelian randomization studies have failed to find a direct effect of HDL-C on CVDs [41, 44]. However, it is reasonable to assume that we cannot ascertain the cause of this decrease in HDL-C and the role it may have on assessing the overall impact of oat intake on CVD risk. Future studies should explore how oat intake may affect different types of HDL-C particles, such as small-sized HDL-C, as well as their implications on cardiometabolic health [45].

A growing body of epidemiological studies [46,47,48,49,50,51] has consistently shown an inverse relationship between dietary fibre intake (such as those found in oats) and body weight. This report found a significant change in BMI, body weight and WC in the main meta-analysis. We observed similar effects and direction for BMI in the pooled analyses of OSIs + DR vs. DR alone. These findings suggest that the extent of health effects of an OSI on body morphology may be highly dependent on the background diet. When considering the effects of OSIs on BMI, body weight and/or WC, it is important to consider EFSA’s scientific requirements for health claims related to such parameters [52]. In particular, it should be taken into consideration that the duration of an intervention required to evaluate body weight should be at least 12 weeks and imaging data by established techniques (e.g., dual energy X-ray absorptiometry, magnetic resonance imaging or computed tomography) are generally appropriate to assess changes in body composition in human intervention studies. In our systematic review there were 20 RCTs with a duration of 12 weeks or more. In addition, not all interventions in RCTs were isocaloric, thus limiting our understanding of the impact of OSIs on obesity. Future clinical trials are needed to help address this question.

Effects of an OSI on BP were only observed for diastolic BP, in the case of OSI + DR vs. DR alone. This change (i.e., WMD: − 1.15 mm Hg, 95% CI (− 2.03; − 0.28)) was inconsistent in other types of interventions and not found in case of systolic BP. A similar inconsistency was observed for glucose homeostasis markers, where significant differences were observed for HbA1c only in RCTs comparing OSI + DR versus DR alone and for glucose for RCTs comparing OSIs vs. no OSIs. No significant differences were observed in any other intervention or in interventions comparing an OSI with heterogeneous controls, regarding any glucose homeostasis marker. A meta-analysis of RCTs evaluating the effects of oat products on glycaemic control among diabetic patients indicated that the effects of oats and oat beta-glucans on glycaemic control and insulin sensitivity are inconclusive [5]. In line with our work, a systematic review on oat intake and its association with CVD risk markers did not find convincing evidence of oat influence on insulin sensitivity and emphasized the importance of exploring additional CVD markers [4]. However, it has been proposed that the glycaemic benefits of oats are directly dependent on the structural integrity of the oat kernel, β-glucan’s dose, molecular weight and comparison [13, 53,54,55]. Even though our findings were based on a limited number of studies focused on OSIs and glucose homeostasis, they still suggest some benefits for the later and thus warrant the need for further more rigorous research.

Strengths, limitations and recommendations for future research

To the best of our knowledge, this is the first study to provide a comprehensive analysis on the role of OSI on several CVD risk markers, accounting for background diet and control arms. To identify as many relevant studies as possible and reduce the risk of publication bias, a highly sensitive search strategy was used and additional resources were searched including the reference lists of included trials and relevant systematic reviews. Conventional funnel plots and Egger test estimates showed only a minimal publication bias; still, these methods are limited by their qualitative nature and we cannot exclude the possibility of measured or unmeasured publication bias. Location of study and percentage of male participants contributed to the heterogeneity of findings, and the OSI’s dose and duration were highly variable. Thus, future studies exploring the role of sex, ethnicity and cultural factors in the association of OSIs and risk of CVD are warranted. Our findings need to be interpreted cautiously, with considerations of the specific comparison food/diet. Also, only 36 out of 74 RCTs (48.6%) took isocaloric diet between arms into account, and whether these differences affect the results should be explored by future studies.

Conclusion

Supplementation of diet with oat cereals improves CVD risk markers among healthy adults and those with mild metabolic disturbances, particularly by influencing serum total and LDL cholesterol, BMI and WC. The beneficial effects on TC and LDL-C were independent of the dietary background. The role of OSIs on BP, glucose homeostasis or other markers, could not be established.